GlassScriptPhysician profile
Raven Aravind
NPI 1518592534
$1,599.96
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $478 · 2024: $25.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $25.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $25.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $331.79 | 2021-2022 | |
| Janssen Biotech, INC. | $157.32 | 2021-2022 | |
| Pfizer INC. | $88.81 | 2021-2022 | |
| Amgen INC. | $84.54 | 2021-2022 | |
| Astellas Pharma US INC | $80.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $79.76 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $72.70 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $53.07 | 2021-2022 | |
| Eisai INC. | $47.46 | 2022 | |
| Sobi, INC | $46.01 | 2022 | |
| Glaxosmithkline, LLC. | $45.95 | 2021 | |
| Merck Sharp & Dohme LLC | $45.91 | 2021 | |
| Foundation Medicine, INC. | $41.62 | 2022 | |
| Puma Biotechnology, INC. | $39.08 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $37.89 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.85 | 2021 | |
| Morphosys, US INC. | $35.93 | 2021 | |
| Gilead Sciences, INC. | $33.50 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $32.48 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $27.06 | 2022 | |
| Boston Scientific Corporation | $25.41 | 2024 | Watchman Flx |
| Teva Pharmaceuticals USA, INC. | $23.47 | 2021 | |
| Dova Pharmaceuticals | $22.83 | 2021 | |
| Celgene Corporation | $20.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $19.75 | 2022 | |
| Array Biopharma INC | $18.47 | 2021 | |
| Incyte Corporation | $17.69 | 2021 | |
| Taiho Oncology, INC. | $16.79 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raven Aravind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.